CEL and arthritic joint disease: Clinical scoring showed that although the incidence of disease development (arthritis score≥1) was 100% in all groups (data not shown), treatment with CDV15 anti-BSSL antibodies at the higher dose (5 mg/kg per injection) significantly reduced disease severity as compared to both etanercept and PBS (p<0.05 from day 17 onwards; Fig. 7A).